Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
about
RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1Mechanisms involved in the development of chemotherapy-induced neuropathyChemotherapy-induced peripheral neurotoxicity: a critical analysisAAPT Diagnostic Criteria for Chronic Cancer Pain ConditionsNatural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic reviewSimvastatin Sodium Salt and Fluvastatin Interact with Human Gap Junction Gamma-3 ProteinIdentifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics TechnologyPathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis.Platinum-induced neurotoxicity and preventive strategies: past, present, and futureCalcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?New tools for the quantitative assessment of prodrug delivery and neurotoxicity.Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral NeuropathyTranslational approaches to treatment-induced symptoms in cancer patients.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.Chemotherapy-induced peripheral neuropathy: Current status and progress.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.Bortezomib-induced peripheral neurotoxicity: an update.Novel composite drug delivery system as a novel radio sensitizer for the local treatment of cervical carcinoma.HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.Translational research and symptom management in oncology nursing.Pain in chemotherapy-induced peripheral neurotoxicity.Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.Platinum-induced neurotoxicity: A review of possible mechanisms.AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.Axonal Transport Impairment in Chemotherapy-Induced Peripheral NeuropathyVoltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN).Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN).Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer PatientsPharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity.
P2860
Q24273390-6E4FE1ED-6CF0-461C-81A1-426D8726DA47Q26824380-A96AB0D9-6AF3-4A9E-9186-59904E47E45EQ27010318-2CD5624D-A5BE-47FB-A68A-8C94E9818D6BQ28079708-3D22749B-1AC8-4D18-AE3F-E0D3EFA25F6CQ28270819-AE35F62F-CBCE-4183-824A-47E3A1169092Q28550067-782AF960-1CF4-449B-8B34-274EDC66ACC5Q28551798-45752780-6356-4CE0-B799-15BE9D6DD42CQ33744706-E62CEE85-A291-41CD-B0CD-53929CA61848Q34733071-24680E0A-E93E-4A11-BC61-12D444E9C0F7Q35345734-D2B3F544-F532-4A62-8B8F-675D6C5B0530Q35642335-D00E80AF-384F-4893-A75E-EC5570694193Q35849165-1E027A78-FB0E-4BD8-8AEE-0F4886C16042Q36057728-8ACA349D-2F99-4CA6-9FE6-992F7047F3F2Q36117686-614C93EC-1F0A-4184-8464-810CC2A53D69Q36143029-C7924DA5-6FEB-45FA-AA55-174C3A85AEAEQ36226275-22A0F5D1-8638-440F-A433-ED5D446F30A2Q36243420-ACFB7353-96F3-4D4F-9EB3-D6F3BDAFA7FCQ36344699-063EBD91-047A-4609-97E3-4A6FE80626B5Q36421901-312A656E-2BCD-428E-96B3-58DF7DF78A99Q36551631-3E3CE115-83DB-4448-A33A-0E689169E5DCQ37325728-C1D02D0F-7B5E-4285-A375-CD7687D88F20Q37383249-708AEC3D-4E85-4067-B230-6C56EEC98192Q37659699-07B084BC-A752-45B2-98A1-8D2D9F97856EQ37744263-2D94EA46-8028-404B-9DC8-A153EBF19B24Q38224422-248CA927-F138-4265-A311-D863C30ABC23Q38234733-E654366B-6B4C-4D3A-AC47-219462B4BEA7Q38630235-10C4F215-0622-48F3-A97C-1D4A89096C64Q38707311-533D961B-F7F4-4AD6-B00C-A1C580404211Q38845822-1BDA6822-0668-4075-978F-6A793B90161BQ39363713-60B53897-A8F2-4AC3-973B-CCD0469E744EQ39858558-72E4F56E-6B52-4D46-A331-6889A0B77867Q41095276-DC061C38-C8CB-40BD-9A9E-36504E9925A0Q41374593-74ED9B03-121B-4CB2-B000-EE80B53234B2Q41495258-7DDB0624-E4B2-4D4B-BEE6-B8117C3ED576Q42361415-3A5A2592-A9B4-445E-ABB0-FB1D3ED2905AQ44304377-1F301B6F-9744-4301-A82E-80441BB1F149Q45356332-8D0408C3-ABBD-488C-B5A9-6FF46216F1AAQ46719997-77D7CD97-6D16-4C44-80AD-85B8A73E133EQ47207401-EF5AC08C-8C55-4090-AB20-45E1119BAFE1Q47344383-6511EEA4-5CD5-4417-AA6A-2F526D3B64D6
P2860
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
@en
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
@nl
type
label
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
@en
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
@nl
prefLabel
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
@en
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
@nl
P921
P1433
P1476
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
@en
P2093
Paola Marmiroli
P304
P356
10.1016/S1470-2045(11)70131-0
P577
2011-06-28T00:00:00Z